CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP)

CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP)

Bibliographic Details
Main Authors:	Lim, S, Hale, G, Marcus, R, Waldmann, H, Baglin, T
Format:	Journal article
Published:	1993

Similar Items

CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura.
by: Lim, S, et al.
Published: (1993)

Adult idiopathic thrombocytopenic purpura.
by: Mead, A, et al.
Published: (2003)

Thrombotic thrombocytopenic purpura with terminal pancytopenia.
by: Ng, S.C., et al.
Published: (1990)

Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial)
by: Estcourt, L
Published: (2019)

Purtscher retinopathy as an initial presentation of thrombotic thrombocytopenic purpura
by: Tajunisah, I., et al.
Published: (2010)

Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy
by: Provan, D, et al.
Published: (2003)

The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
by: Willis, F, et al.
Published: (2001)

Campath-1H therapy in refractory ocular inflammatory disease.
by: Dick, A, et al.
Published: (2000)

A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura.
by: Brunskill, S, et al.
Published: (2007)

Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura.
by: Szende, A, et al.
Published: (2010)

Helicobacter pylori Eradication in Patients with Immune Thrombocytopenic Purpura: A Review and the Role of Biogeography
by: Beck, Paul L., et al.
Published: (2017)

Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.
by: Killick, S, et al.
Published: (1997)

Spontaneous subdural hemorrhage in immune-thrombocytopenic purpura with Concomitant liver cirrhosis: a case report
by: Hayati Firdaus, et al.
Published: (2016)

MEASUREMENT OF HEALTH UTILITY VALUES IN THE UK FOR HEALTH STATES RELATED TO IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA (ITP)
by: Szende, A, et al.
Published: (2009)

Specificity of monoclonal antibody Campath-1.
by: Hale, G, et al.
Published: (1988)

Availability of Campath-1 antibodies for bone marrow transplantation.
by: Hale, G, et al.
Published: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
by: Hale, G, et al.
Published: (1994)

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H
by: Watts, R, et al.
Published: (1992)

CAMPATH: from concept to clinic.
by: Waldmann, H, et al.
Published: (2005)

CAMPATH-1H in inflammatory arthritis.
by: Watts, R, et al.
Published: (1993)

The CAMPATH-1 antigen (CDw52).
by: Hale, G, et al.
Published: (1990)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
by: Hale, G, et al.
Published: (2002)

REMISSION INDUCTION IN PATIENTS WITH LYMPHOID MALIGNANCIES USING UNCONJUGATED CAMPATH-1 MONOCLONAL-ANTIBODIES
by: Dyer, M, et al.
Published: (1990)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
by: Hale, G, et al.
Published: (1988)

Posttransfusion Purpura
by: Murphy, M
Published: (2013)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
by: Hale, G, et al.
Published: (1996)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
by: Waldmann, H, et al.
Published: (1987)

Post-Tranfusion Purpura
by: Murphy, M
Published: (2009)

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
by: Novitzky, N, et al.
Published: (2004)

CAMPATH-1 antibodies in stem-cell transplantation.
by: Hale, G, et al.
Published: (2001)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
by: Williams, R, et al.
Published: (2000)

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen.
by: Xia, M, et al.
Published: (1993)

ISOTYPE VARIANTS OF CAMPATH-1 ANTIBODY - REQUIREMENTS FOR EFFECTIVE ANTIBODY ACTION INVIVO
by: Dyer, M, et al.
Published: (1989)

Peripheral blood dendritic cells express CD52 and are depleted in-vivo by treatment with CAMPATH-1H.
by: Buggins, A, et al.
Published: (2001)

INVITRO TREATMENT OF MARROW WITH ATCG OR CAMPATH-1 FOR PROPHYLAXIS OF GVHD - RESULTS OF THE AG-KMT MUNCHEN
by: Kolb, H, et al.
Published: (1985)

Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.
by: Hale, G, et al.
Published: (1988)

Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies.
by: Lockwood, C, et al.
Published: (1996)

CAMPATH-1 FOLLOWING RENAL-TRANSPLANTATION - A RANDOMIZED TRIAL
by: Friend, P, et al.
Published: (1988)

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.
by: Dyer, M, et al.
Published: (1989)

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.
by: Isaacs, J, et al.
Published: (1996)